



"CAPTURING CANCER COMPLEXITY AND CLINICAL CHALLENGES"

CCBIO1 Newsletter

 EDITOR: eli.vidhammer@uib.no

DIRECTOR'S COMMENTS

Dear all

We have lots of information for you in this first CCBIO Newsletter after the summer break, reflecting a range of activities supporting excellent science, education and communication. The INTPART network meeting on Iceland between the Akslen and Strand groups from UIB and several groups from the Vascular Biology Program at Boston Children's Hospital and Harvard Medical School in Boston. Thanks very much to the main INTPART coordinator and meeting organizer Elisabeth Wik and co-organizer Michael Rogers (VBP) for their efforts. The meeting was a success with "eruptions" of scientific data, ideas, and discussions, with many examples of scientific "saga telling", and for the integrated focus on "philosophy of science", among other topics. Very encouraging "seeds" were presented in the unique surroundings on Iceland.

The CCBIO students visiting Boston this summer have written about their many experiences. Please also read about upcoming meetings and courses on different topics, and about new publications from CCBIO, including Line Bjørge as a co-author on the important AVANOVA2 study published in Lancet Oncology.

CCBIO scientists are happy to congratulate Professor Bruce R. Zetter who will receive an Honorary Doctorate at UIB on October 15, 2019. Bruce will present a special research seminar on October 14 at 14:15 (Store Auditorium Haukeland University Hospital). You are all welcome to the seminar and to the reception afterwards.

Best regards, Lars A. Akslen, Director

Programs and Research Teams

Mechanisms of Tumor-Microenvironment Interactions:

- Donald Gullberg
- Karl-Henning Kalland
- Emmet McCormack

Exploration and Validation of Cancer Biomarkers:

- Lars A. Akslen
- Jim Lorens
- Camilla Krakstad
- Daniela Costea
- Elisabeth Wik

Clinical Applications and Trial Studies:

- Bjørn Tore Gjertsen
- Oddbjørn Straume
- Line Bjørge

Health Ethics, Prioritization and Economics:

- Roger Strand
- John Cairns
- Ole Frithjof Norheim

Additional resource: Bioinformatics and Big Data

- Inge Jonassen

Centre Director:

Prof. Dr. Med Lars A. Akslen
+ 47 55 97 31 82 lars.akslen@uib.no

Administrative Leader:

Geir Olav Løken
+ 47 55 58 54 36 geir.loken@uib.no

Support for grant applications:

Yves Aubert
+47 55 58 89 69 Yves.Aubert@uib.no

All administrative officers: [link.](#)

www.ccbio.no

STIMULATING SCIENTIFIC ERUPTIONS

Iceland's dramatic landscape served as backdrop for generating ideas and action plans for new collaborations between the University of Bergen/CCBIO and Harvard Medical School/the Vascular Biology Program in a meeting August 29th to September 3rd.

Iceland turned out to be a perfect meeting place more or less halfway between Bergen and Boston. The organizers, Elisabeth Wik and Assistant Professor Michael Rogers at Harvard Medical School/Boston Children's Hospital, backed up by the initiators Professor Lars A. Akslen, Professor and CCBIO PI Roger Strand, and Professor Marsha Moses, Director of the VBP at Boston Children's Hospital, wanted this meeting to enable cross-fertilization between groups and to generate ideas and action plans for new collaborations. Interaction and ad hoc meetings should be the primary focus. See [full report here](#), or shorter [web article](#).



Presentations from senior and junior researchers, and scientific talks walking between tectonic plates. Photos: Eli Vidhammer.

AVANOVA2 STUDY PUBLISHED IN LANCET ONCOLOGY

Niraparib in combination with bevacizumab, a novel chemotherapy-free regimen, may be at least as effective as conventional chemotherapy in relapsed ovarian cancer. The study, co-authored by Line Bjørge, is considered of great importance in the field of gynecologic cancers.

AVANOVA is a NSGO sponsored study performed in four Nordic countries and in the USA in collaboration with the European Network for Gynecological Oncological Trial Groups [ENGOT]. This randomized study was designed to develop a chemotherapy-free regimen for ovarian cancer patients who are in relapse and it met its primary endpoint of a statistically significant improvement in progression-free survival compared to niraparib alone. These results were presented in the oral session of ASCO2019 and chosen as "Best of ASCO".

The study Chair of AVANOVA, Mansoor Raza Mirza said: «Niraparib in combination with bevacizumab as treatment of ovarian cancer patients in relapse provides a great opportunity for our patients to be treated with a chemotherapy-free regimen, hence significantly delaying the use of conventional chemotherapy and associated toxicity. As the progression-free survival benefit seems to be comparable to the one achieved with chemotherapy, the combination deserves to be tested against chemotherapy in phase III setting. »

You can [read the publication here](#).

ALTERNATIVE SPLICING REGULATION

The first CCBIO Seminar this fall term was by [Dr. Sushma-Nagaraja Grellescheid](#), who welcomes collaborative projects on alternative splicing and biomarker discovery with CCBIO affiliates, and she announced two available Postdoc positions, one in bioinformatics / computational biology (biomarkers in breast cancer), and one in experimental molecular biology (open choice of project in RNA biology).



Dr. Grellescheid is Assistant Professor in RNA Genomics at Durham University, and Associate Professor at the Computational Biology Unit (CBU) and Department of Biological sciences (BIO) at the University of Bergen. She gave a talk on the role of alternative splicing regulation as regulator of development and ageing, and a driver of disease progression in various diseases, including cancer. (See [abstract](#).) The seminar was well-attended, reflecting the broad interest in the topic, and Dr. Grellescheid highlighted the fact that the target genes of dys-regulated splicing factor levels represent an important but poorly understood class of biomarkers.

REPORT FROM THIS SUMMER'S BOSTON INTERNS

This summer, CCBio sent their second batch of students to be Boston summer interns in the CCBio/Harvard INTPART collaboration. Read the full report from Hanna Dillekås, PhD candidate in Oddbjørn Straume's group, Ridhima Das, PhD candidate in Dana Costea's group, and Amalie Fagerli Tegnander, medical student affiliated to Elisabeth Wik's project.

Amalie was at [Dr. Randy Watnick's laboratory](#). As a first year medical student, Amalie felt the Boston stay was a flying start into the world of research, and she has thrown herself at her own project in Bergen with great dedication and motivation.

Ridhima was at [Dr. Diane Bielenberg's lab](#), mainly working with tumor lymphatics, and she was also part of a pre-clinical drug trial using semaphorins. Ridhima feels she has expanded her view on cancer research, is highly motivated and has learned a lot to use in her PhD work.

Hanna was assigned to [Dr. Michael Rogers' lab](#) and [Dr. Zetter's lab](#), and reports that this was an amazing and unique experience where she has been inspired, challenged, learnt a range of different lab techniques, improved presentation skills and critical reading of papers, planning of experiments and a lot more.

Read the [full report here](#).



Amalie, Hanna and Ridhima, watching the Red Sox play baseball at Fenway.



NEW POSTDOCS AND PHD APPOINTED

Meet 3 new additions to our groups; Postdoc Maria Lie Lotsberg in Jim Lorens' group, Postdoc Heidrun Vethe in Lars Akslén's group, and PhD Student Jiyeon Kang in Professor John Cairns' group.



Maria Lie Lotsberg

Born 1989, holds an MS in Nanoscience from UiB. She did her PhD in the Lorens and Akslén groups, working on the role of AXL and the tumor microenvironment in cancer cell plasticity and therapy responses in models of non-small cell lung cancer (NSCLC). Maria is now a CCBio Postdoctoral Fellow working in the Lorens group, and her research is focused on identifying biomarkers reflecting the microenvironmental complexity of human cancers, the interaction between cancer cells and the microenvironment, and how this influences aggressive tumor features and patient prognosis.



Heidrun Vethe

Holds an M.S. in Medical Cell Biology and a PhD focusing on stem cells research and diabetes, both from UiB. As a postdoctoral fellow at CCBio in the Tumor Biology Research Group, led by Lars A. Akslén, her research focus is on identifying protein biomarkers and novel targets in aggressive breast cancer, with a special emphasis on the tumor microenvironment, using mass spectrometry-based proteomics, imaging mass cytometry and immunohistochemistry.



Jiyeon Kang

From South Korea, holds an MSc in Global Health from London School of Economics (LSE). As a pharmacist, she has worked in clinical practice and health policy for few years. She is currently doing her PhD in how real-world data could be utilised in economic evaluations of targeted cancer therapy supported by CCBio under the supervision of Professor John Cairns at LSHTM.

Jiyeon has previously worked in hospital, community pharmacy, and Korean HTA (Health Technology Assessment) agency. Her main research interests are health technology assessment in terms of health economics and economic evaluation of cancer treatments.

PROFESSOR BRUCE ZETTER TO BE HONORARY DOCTOR AT THE UNIVERSITY OF BERGEN




The University of Bergen is appointing 10 new honorary doctors, one of which is Harvard Professor Bruce Zetter, very well known to the CCBio family, both as advisor in the CCBio Scientific Advisory Board, and through the CCBio-VBP INTPART collaboration.

"I am very happy that the nomination of Bruce R. Zetter was successful and that he will now be appointed as an Honorary Doctor at UIB," says CCBio Director Lars A. Akslen. "For many years he has supported UIB in many ways, as a scientist, an advisor, and a very skilled teacher and mentor. As a cancer researcher, Bruce is a living legend. His focus on guiding young people towards a career in science is truly unique. CCBio would like to congratulate Bruce with this honor. It's very well deserved." [Read more here.](#)

Also note **Dr. Zetter's guest lecture** in connection with the appointment of Honorary Doctor, **October 14th at 14:14-17:00**, Store Auditorium. All are welcome, just remember to register for the event. [See details here.](#)

MAPPING ORAL CANCER PREVENTION IN EURASIA COUNTRIES

The collaboration project for education and research in oral pathology between Norway, Moldova, Belarus and Armenia is an important internationalization project financed by DIKU through the Eurasia program. Within this project, UIB/CCBio is currently hosting a master student, Olga Golburean, a graduated dental hygienist who is taking her master degree in global health with Professor Dana Costea and Associate Professor F. Ozkaya as supervisors.



Olga has recently been on a comprehensive visit to the collaborating countries. In her master project, she is mapping the knowledge, attitudes and practices of dental professionals in Moldova, Belarus and Armenia regarding oral mucosal examination and oral cancer prevention. We had a talk with Olga about her project, and the impressions she got from visiting no less than 330 clinics in the 3 collaborating Eurasia countries.

[See interview here.](#)

SUPPORT CCBIO PHD CANDIDATE AT THE RESEARCHER GRAND PRIX 2019

Hilde Renate Engerud, PhD candidate in the Bergen Gynaecologic Cancer Research Group, is participating in the "Forsker Grand Prix 2019" in connection with the national Research Days 2019. She will be on stage September 25th in the Bergen heat, at Mimes Brønn, Høgskolen i Bergen, Campus Kronstad.

She is one of 10 selected researchers to present their research, each given 4 minutes to make an impression. Doors open at 18.00, and the show starts at 19.00. The two best will proceed to the national final in Stavanger September 28th. [See website.](#)

Hilde will be presenting her research on biomarkers for prognosis and treatment of uterine cancer. [See interview with Hilde](#) (in Norw.)

And thanks to **Henriette Ertsås** for a great interactive show at this year's Research Fair in Bergen, September 21st!

"Lots of kids got to try the "Genetic Code" and experience the good collaboration in a epithelial team," Henriette explains. "Those who thought there were too many codes and rules, could do "typos" at their own convenience, in the role of UV light or alcohol. Luckily, others stepped in as correction enzymes. Some adults learnt what a mutation actually is, and others told us of the side effects they experienced from experimental cancer therapy. This was an important occasion where researchers and the public could interact," Henriette concluded.

See news [article in Bergensavisen](#) featuring Henriette, aka Stine Stamcelle.



Henriette, here as a fat cell.
Photo: Lars Thorøsen

Forsker Grand Prix 2019

Forsker grand prix arrangeres i Bergen **25. september** i Mimes Brønn på Høgskolen i Bergen, Campus Kronstad. **Dørene åpner kl. 18.00.** Showet starter kl. 19.00

10 forskere får fire minutter hver til å engasjere publikum og dommere.

10 i den innledende runden vil de ti forskerne presentere sin forskning på fire minutter, men kan tre gå videre til finalerunden. Her får de fire nye minutter til å fenge både publikum og dommere. Forskerne har brukt lang tid til å forberede seg, men hvem klarer å gå til topps når det virkelig gjelder? De to beste forskerne går videre til den nasjonale finalen i Stavanger 28. september.

Programledere:
Roe Lauvdal jr.

Dommerpanel:
Sofrid Bratland-Sanda, Akademiet for yngre forskere
Kjetil H Dale, TV2
Lukke Kjosvold-Møen, Hordaland Teater

BILLETTER

Årets Forsker Grand Prix kandidater

Hilde Renate Engerud
Klinisk institutt 2, Universitetet i Bergen

Visste du at livmorkræft er den vanligste kreftformen hos kvinner etter bryst-, tarm- og lungekreft? Og at antall tilfeller er økende?

I min doktorgrad forsker jeg på livmorkræft med mål om å finne markører som bedre kan si noe om prognose og veivise valg av behandling. Livmorkræft: forskningen i løvets blomsterblad og er en annen krefttype enn den nye ormstabe livmorhalskreft. Totalt sett har livmorkræft gode prognoser. Likevel opplever 15-20% av kvinnene tilbakefall og fremtidsutsikterne er dårlig ved spredning og avansert sykdom.

I klinisk bruk i dag har man få kreftmarkører som kan si noe om prognose og som kan veivise behandling for livmorkræft. Det er derfor avgjørende å finne nye markører som bedre kan si noe om sykdomsforløpet, og som bedre kan bidra til mer personilpasset behandling.

Facsimile from the Forsker Grand prix website. Photo: Andrea Magugliani

4TH SCANDINAVIAN TRANSLATIONAL PATHOLOGY MEETING 2019

We are happy to invite you to the 4th Scandinavian Translational Pathology Meeting (SCANPATH), October 23-24, at beautiful surroundings at the historical Solstrand Hotel, nearby Bergen, Norway. Registration is now open!

SCANPATH is an annual network meeting for Scandinavian tumor pathologists and pre-clinical scientists with an interest in the prospects of next generation tissue profiling. The meeting was initiated by CCBIO in 2016 and co-organized by CCBIO in 2017, and now also in 2019. The aim is to stimulate tissue-based studies of tumor mechanisms and biomarker mapping. This initiative has been a success and SCANPATH is now a well established annual forum.

Similar to previous years, the seminar will include inspirational speakers representing the different research groups attending the meeting.

See [preliminary program](#) and [more information here](#), incl. registration.



Photos: Gei Olav Løken and Eli Vidhammer

COMING CCBIO RESEARCH SCHOOL COURSES

We are happy to announce the fall term courses, including a brand new course!

Clinical Trials in Cancer Research

[Line Bjørge](#) and [Hani Gabra](#) are responsible for a brand new course, titled "Clinical Trials in Cancer Research". The course is designed to prepare the participants to conduct clinical trials in humans. The modules included will be based on the ICH_GCP, and the participants will receive a certificate in Good Clinical Practice on completion of the course.

The course will consist of 6 different modules, covering:

- General principles
- Operations
- Formalities
- Regulations
- Success factors
- Clinical trials in the future

When: October 3 and 4, 2019

[Read more here](#). *Note that this course is soon fully booked, so be quick!*



Illustration: www.colourbox.com

Wonder when the other CCBIO courses are scheduled? Then see [this page](#).

CCBIO903 Cancer research: Ethical, economic and social aspects

The course focuses on ethical, economical and societal aspects of cancer and cancer research and aims to equip PhD candidates with tools for systematic reflection on their own and related research as well as methods for assessing the cost benefit of health measures and methods of treatment.

[John Cairns](#), [Roger Strand](#) and [Anne Blanchard Bremer](#) are responsible for the course. The course provides 5 ECTS.

When: December 9-13 2019 and January 6-9 2020.

[Read more here](#).



Illustration: Lightspring/Shutterstock

CCBIO MINI SYMPOSIUM ON CLINICAL TRIALS IN THE FUTURE

Welcome to a CCBIO Mini Symposium October 4th on the topic "Clinical trials in the future". Join us for interesting lectures and discussions, and top it off with a pizza get-together!



Invited speakers:

Fredrik Öhrn, Gothenburg: Design of clinical trials in the future

Tove Skjelbakken, Tromsø: Decision aids

Donal Landers, Manchester: Digital experimental medicine in oncology

Ketil Widerberg, Oslo: How artificial intelligence can improve clinical trials

When: Friday October 4th 2019, at 12:30 to 15:00

Where: Auditorium 4, BB-building, Jonas Lies vei 91 (Haukeland Campus), Bergen

Who: The seminar is open to all, free of charge and includes a pizza get-together following the seminar. No registration needed.

Chairpersons: [Line Bjørge](#) and [Hani Gabra](#).

NEW PHD ANNOUNCEMENTS

Note that a new CCBIO PhD announcement is currently in the JobbNorge portal, and a couple more is on the way.

The announced PhD position is a full-time (100%) temporary PhD-position is available for a period of three (3) years. The position is part of the project "Exploring age-related breast cancer biology" (CCBIO Program 2), funded by the University of Bergen.

By this project, we aim to identify biomarkers with clinical relevance, explaining some of the increased tumor aggressiveness seen in breast cancer of the young, with potential for improving individualized treatment and outcome. Integrated analyses of genetic, transcriptomic and proteomic data, and other tissue analyses, including morphologic measures, are central approaches.

Note **deadline October 6th** 2019. Spread the word!

For the currently announced PhD position and future CCBIO positions, you can [consult this link](#).



RECENT DOCTORAL DEFENSES



Sahba Shafiee defended Thursday June 20th 2019 her doctoral dissertation "Translational Development of Preclinical Models and Therapies in Myelodysplastic Syndromes (MDS)". Main supervisor was Professor Emmet McCormack and co-supervisors were Associate Professor Astrid Olsnes Kittang and Professor Bjørn Tore Gjertsen.

[See announcement.](#)




Kjersti Tefre Davidsen defended Friday June 21st 2019 her doctoral dissertation "The Receptor Tyrosine Kinase Axl in Tumour Phenotypic Plasticity and Acquired Resistance to Cancer Targeted- and Immunotherapy". Main supervisor was Professor James Lorens and co-supervisor was Professor Oddbjørn Straume. [See announcement.](#)

CCBIO SEMINARS

Make sure to note the coming CCBIO Seminars, starting **September 26th** at 14:30 with [speaker Karl Kadler](#), Director at the Wellcome Trust Centre for Cell-Matrix Research, Manchester, UK.

Title of Professor Kadler's talk is "Circadian control of the secretory pathway is a central mechanism in tissue homeostasis." See more info and [abstract](#).

Note also **October 31st** with [speaker Dana Costea](#), and **November 28th** with [speaker Curzio Ruegg](#).



From CCBIO Special Seminar September 18th by Professor Bruce Baguley from Auckland Cancer Society Research Centre at the University of Auckland, New Zealand. There was great interest in his talk: 'Do human cancer cell lines really behave in the same way as clinical tumour material?' Photo: Austin Rayford

COMING CCBIO EVENTS

Make sure to save the dates in your calendar, and register when applicable. You can see all planned CCBIO events in the CCBIO web calendar.



- September 26, CCBIO Seminar, speaker Karl Kadler. Title: "[Circadian control of the secretory pathway is a central mechanism in tissue homeostasis](#)"
- October 3-4, CCBIO course "[Clinical Trials in Cancer Research](#)", Bergen
- October 4, CCBIO Mini Symposium "[Clinical Trials in the Future](#)"
- October 14, [Honorary Doctorate lecture by Dr. Bruce Zetter](#). «RNA as a tool for cancer therapy».
- October 23-24, the [4th Scandinavian Symposium in Translational Pathology](#), Bergen (Solstrand)
- October 31, CCBIO Seminar, [speaker Dana Costea](#).
- November 7, [CCBIO Junior Scientist Symposium](#)
- November 28, CCBIO Seminar, [speaker Curzio Ruegg](#).
- December 12, CCBIO Seminar, speaker tba
- December 9-13, [CCBIO903 Cancer research: Ethical, economic and social aspects](#), Bergen

OTHER COMING EVENTS



Illustrations: www.colourbox.com

- September 26-27, [Personalised Cancer Therapy – Biomarkers in Clinical Trials Project Meeting](#), Stavanger.
- October 4, [STRAT-CELL kick-off symposium](#), Oslo.
- October 14-16, [Folkehelsekonferansen 2019](#), Oslo.
- October 16, [I-O Educational Meeting 2019: Making Treatment Decisions for and with Your Cancer Patients](#), Oslo Cancer Cluster event, Oslo. Will also be streamed.
- October 22, [Forskingsdata](#): åpne forskningsdata og hvordan forberede og lagre forskningsdata. Bibliotek for medisin, 3. etasje, BBB, Bergen.
- November 3-6, [International p53/p63/p73 Isoforms Workshop](#), Dubrovnik, Croatia (JC Bourdon is main organizer and the conference also features Bjørn Tore Gjertsen)
- November 4-8, [Metabolic Pathway Analysis course](#), Trondheim, Centre of Digital Life Norway.
- November 6-7, [A Good Ending – Good for All](#), international conference on quality of care for cancer patients, Bergen.
- November 6-8, [hands-on workshop on data standards and data management](#), Trondheim, Centre of Digital Life Norway.
- November 11. [EHIN, conference on e-health in Norway](#), Oslo Cancer Cluster, Oslo.
- November 11-13, [BIO-Europe 2019](#), Hamburg
- December 4-5, [Nordic-American Life Science Conference 2019](#), New York.
- January 16, [Cancer Crosslinks 2020](#), Oslo Cancer Cluster. (Registration will open in October.)

PUBLICATIONS

You can find the CCBIO publications [on this pubmed link](#). See the last 5 below.

Illustration: Colourbox.com

- Tsuruda KM, Bhargava S, **Akslen LA**, Bjørndal H, Hofvind S. [Forløpstider i Mammografi-programmet før og etter innføring av pakkeforløp for brystkreft](#). Tidsskr Nor Laegeforen. 2019 Sep 9;139(12). doi: 10.4045/tidsskr.18.0322. Print 2019 Sep 10. Norwegian.
- Austdal M, Silva GB, Bowe S, Thomsen LCV, Tangerås LH, **Bjørge L**, Bathen TF, Iversen AC. [Metabolomics Identifies Placental Dysfunction and Confirms Flt-1 \(FMS-Like Tyrosine Kinase Receptor 1\) Biomarker Specificity](#). Hypertension. 2019 Sep 9:HYPERTENSIONAHA11913184. doi: 10.1161/HYPERTENSIONAHA.119.13184. [Epub ahead of print]
- Terry S, Abdou A, Engelsen AST, Buart S, Dessen P, Corgnac S, Collares D, Meurice G, Gausdal G, Baud V, Saintigny P, **Lorens JB**, Thiery JP, Mami-Chouaib F, Chouaib S. [AXL targeting overcomes human lung cancer cell resistance to NK and CTL-mediated cytotoxicity](#). Cancer Immunol Res. 2019 Sep 5. pii: canimm.0903.2019. doi: 10.1158/2326-6066.CIR-18-0903. [Epub ahead of print]
- Eble JA, **Gullberg D**. [What Is the Fuss about Integrins and the Tumor Microenvironment?](#) Cancers (Basel). 2019 Sep 3;11(9). pii: E1296. doi: 10.3390/cancers11091296.
- Mirza MR, Åvall Lundqvist E, Birrer MJ, dePont Christensen R, Nyvang GB, Malander S, Anttila M, Werner TL, Lund B, Lindahl G, Hietanen S, Peen U, Dimoula M, Roed H, Ør Knudsen A, Staff S, Krog Vistisen A, **Bjørge L**, Mäenpää JU; AVANOVA investigators. [Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer \(NSGO-AVANOVA2/ENGOT-ov24\): a randomised, phase 2, superiority trial](#). Lancet Oncol. 2019 Aug 29. pii: S1470-2045(19)30515-7. doi: 10.1016/S1470-2045(19)30515-7. [Epub ahead of print]

RECENT CCBIO IN THE MEDIA

Recent media appearances by CCBIO PIs and group members. For all media hits, see [CCBIO's web pages](#).



20.09.19, VG, "[Ny behandling gir håp til pasienter med uhelbredelig eggstokkreft: – Største som har skjedd siden immunterapi](#)", Line Bjørge. Also in [ABC Nyheter](#), [Drammens Tidende](#), [Forskning.no](#), [Fjordabladet](#) and more.

18.09.19, Khrono, "[49 unge forskere konkurrerer om ti finaleplasser i Forsker Grand Prix](#)", Hilde Renate Engerud.

06.09.19, Dagens Medisin, "[Ta tak i genomforskningen!](#)", Inge Jonassen.

04.09.19, Khrono, "[Skal undersøke bruken av 6 milliarder forskningskroner](#)", CCBIO.

15.07.19, På Høyden, "[Musikk-medisinen](#)", Bjørn Tore Gjertsen

11.07.19, Helse Bergen, "[Gjennombruddsforskning fra KK om eggstokkreft](#)", Line Bjørge.

10.07.19, VG, "[Ny forskning om eggstokkreft: – Et gjennombrudd](#)", Line Bjørge.

14.06.19, Allers, "[Senskader er svært vanlig](#)", Line Bjørge.

14.06.19, OsloBørs, "[BerGenBio presents preliminary Phase II clinical data at EHA 24: bemcentinib in combination with low dose chemotherapy yields durable responses in AML patients unfit for intensive chemotherapy](#)", Bjørn Tore Gjertsen.

13.06.19, Den norske tannlegeforenings Tidende, "[Om «pakkeforløp» og innsendelse av biopsier](#)", Anne Christine Johannessen.

